The approval of efanesoctocog alfa brings an extended half-life factor VIII replacement to the Australian market, arriving as the country’s clinical trial sector continues to expand its role in global drug development.
Newsflash:
The Series A financing backs a monoclonal antibody licensed from a Chinese biotech, betting that blocking a …
The approval of efanesoctocog alfa brings an extended half-life factor VIII replacement to the Australian market, arriving as the country’s clinical trial sector continues to expand its role in global drug development.
The Series A financing backs a monoclonal antibody licensed from a Chinese biotech, betting that blocking a …
The approval of efanesoctocog alfa brings an extended half-life factor VIII replacement to the Australian market, arriving as the country’s clinical trial sector continues to expand its role in global drug development.
The Series A financing backs a monoclonal antibody licensed from a Chinese biotech, betting that blocking a …
LEADERS
INVESTMENTS
INNOVATION
PARTNERSHIPS
In-Depth Analysis
In-Depth Analysis
Explore our longform features and deep dives into biotech breakthroughs and innovation.
Expert Opinions
Expert Opinions
Read opinions and commentary from leading scientists, investors, and pharma leaders.
Funding & IPOs
Funding & IPOs
Track the latest funding rounds, IPO announcements, and investment trends in biotech/pharma.
Clinical Results & Milestones
Clinical Results & Milestones
Stay informed on pivotal trial results, FDA approvals, and key clinical milestones.
1
2
3
4
5
6
7
8
9
10
1
2
3
4
5
6
7
8
9
10
The Reporter Newsletter
Expert picks and exclusive deals, in your inbox.
BlueRock Therapeutics reports that a single transplant of dopaminergic progenitors derived from pluripotent stem cells produced durable reductions in motor disability in Parkinson’s patients, with Phase 3 enrolment underway
BlueRock Therapeutics reports that a single transplant of dopaminergic progenitors derived from pluripotent stem cells produced durable reductions in motor disability in Parkinson’s patients, with Phase 3 enrolment underway
Watch Now
Depot blast in Bangladesh kills nearly 50 people - BBC News
Russia accused of stealing about 600,000 tonnes of Ukraine's grain - BBC News
Devastation of Australia's climate change crisis captured on camera - BBC News
Boris Johnson survives leadership vote but 41% of his MPs have “no confidence” - BBC News
The approval of efanesoctocog alfa brings an extended half-life factor VIII replacement to the Australian market, arriving as the country’s …
Major investment strengthens pharmaceutical supply chain resilience and advances green manufacturing practices in North America.
Listen Now
Triple-drug combination extending life for women with aggressive HR+/HER2− breast cancer
The donor-derived cell therapy is designed to be infused alongside a stem cell transplant, aiming to reduce a complication that affects roughly half of allogeneic transplant recipients.
Amtagvi becomes the first tumour-infiltrating lymphocyte therapy approved in Australia for advanced melanoma, entering a market with the world’s highest melanoma incidence rate.
The acquisition, announced in March and targeting Centessa’s orexin receptor agonist programme, signals Lilly’s intention to build a CNS platform that extends well beyond its blockbuster GLP-1 franchise
Ready To Explore Industry News?
All articles are free -no payment or registration required.
Already a subscriber?